Rick,
Since a biotoddler is handling this, there are going to be some misses in throwing things into the watch list. No matter, they can be ejected. I've done a quick search of several companies' 10-Ks and 10-Qs.
Starting with BD. Indeed, most of their stuff trickles from patient care, not biotech. Though their biosciences division is the fastest growing, it's still the smallest, accounting for roughly 1/3 of revenue.
Isco's biotrickle percentage (at least for the stuff I'm fairly sure is used in biotech labs) appears to account for less than 20%.
Fisher is a tougher call. They break out their segments in terms of operations and products, more than markets, so it's hard to tell who they're selling to. I would imagine a good deal of their sales go to researchers outside of biotech, but how much is unclear. Any help here?
BDX is clearly a major trickle player, but not pure enough to qualify for this portfolio. Isco's qualifications are even weaker. Fisher remains a question mark to me. I will toss the first two out of the watch list, but keep Fisher until I learn it's not tricklish enough.
Cheers, Tuck |
